This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Avadel Pharmaceuticals Dividenden en inkoop
Dividend criteriumcontroles 0/6
Avadel Pharmaceuticals heeft geen dividenduitkeringen gedaan.
Belangrijke informatie
n/a
Dividendrendement
-0.2%
Terugkoop Rendement
| Totaal aandeelhoudersrendement | -0.2% |
| Toekomstig dividendrendement | 0% |
| Dividendgroei | n/a |
| Volgende betaaldatum dividend | n/a |
| Ex-dividenddatum | n/a |
| Dividend per aandeel | n/a |
| Uitbetalingsratio | n/a |
Recente updates van dividend en inkoop
Geen updates
Recent updates
AVDL: Revised Acquisition Terms And CVR Structure Will Shape Future Risk Balance
Analysts lifted their price target on Avadel Pharmaceuticals to $22.50 from $20, citing improved acquisition terms and updated deal expectations as the key reasons for the change. Analyst Commentary Recent research highlights how the evolving acquisition proposals around Avadel Pharmaceuticals are shaping valuation views and risk assessments for investors following the stock.
AVDL: Alkermes Cash Deal And CVR Structure Will Define Limited Upside
Analysts lifted their fair value estimate for Avadel Pharmaceuticals to $18.50 from $16.00, citing updated acquisition terms, improved contingent value right economics, and revised assumptions around margins and future P/E multiples following recent Street research. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has shifted toward a more balanced and, in several cases, more cautious stance as the Alkermes acquisition framework has taken shape.
AVDL: Cash Deal Terms And CVR Outcome Will Shape Future Returns
Analysts kept their fair value estimate for Avadel Pharmaceuticals at $23.00 per share while adjusting key assumptions, citing the updated Alkermes and Lundbeck proposals and evolving views on Lumryz royalties and contingent value right terms as the main drivers of the new target range around recent Street marks near $20.00 to $22.50. Analyst Commentary Recent Street research around Avadel Pharmaceuticals has centered on the competing acquisition proposals from Alkermes and Lundbeck, as well as the value of Lumryz royalties and the contingent value right, or CVR, tied to potential future approvals.AVDL: Cash Deal And Contingent Payout Will Shape Future Returns
Analysts have trimmed their price target on Avadel Pharmaceuticals to $23.00 from about $31.47, reflecting updated assumptions for slightly higher risk, stronger revenue growth, and sharply improved profitability metrics in light of the evolving Alkermes acquisition dynamics and Lumryz-driven cash flow profile. Analyst Commentary Across recent research notes, bullish analysts acknowledge that headline price targets for Avadel are now clustered in the high teens to low twenties, reflecting the proposed acquisition by Alkermes and the embedded value of the contingent value right tied to Lumryz milestones.AVDL: Acquisition And CVR Milestones Will Define Balanced Risk Reward Profile
Analysts have nudged our fair value estimate for Avadel Pharmaceuticals slightly lower, from $21.06 to $20.94 per share, as they balance modestly reduced long term multiple assumptions with the evolving acquisition landscape and contingent value right dynamics highlighted in recent research. Analyst Commentary Street research reflects a more balanced, wait and see stance on Avadel as the Alkermes transaction and competing interest from Lundbeck reshape the risk reward profile.AVDL: Competing Acquisition Proposals Will Shape Outcomes Amid Industry Uncertainty
Analysts have raised their fair value estimate for Avadel Pharmaceuticals from $19.13 to $21.06 per share. They cite improving profit margins and stronger near-term acquisition prospects as key factors behind the upward revision.AVDL: Future Acquisition to Reshape Sleep Disorder Market Amid Shifting Competitive Risks
Analysts have lowered their price target for Avadel Pharmaceuticals from $20.90 to $19.13 per share. This change reflects recent acquisition agreements and shifting perspectives on the company’s long-term growth prospects.Avadel Settles With Jazz Pharmaceuticals, Gets Acquired By Alkermes
Oct 23Analysts Adjust Avadel Pharmaceuticals Price Target Amid Acquisition and Ongoing Market Developments
Analysts have lowered their price target for Avadel Pharmaceuticals to $20 from previous higher levels. They cite the pending acquisition by Alkermes at $18.50 per share, plus a potential $1.50 contingent cash right, as the primary driver behind the adjustment.Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised their price target for Avadel Pharmaceuticals from $20.30 to $20.90, citing continued commercial momentum for Lumryz. However, they note this optimism is tempered by competitive and market uncertainties.Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts marginally raised Avadel Pharmaceuticals’ price target to $20.30, citing strong commercial execution and growing Lumryz adoption, while noting competitive risks may limit upside. Analyst Commentary Bullish analysts highlight that commercial investments are delivering tangible benefits, evidenced by improved persistency and an expanding number of reimbursed Lumryz patients.Rising Awareness Of Sleep Disorders Will Drive Future Demand
Analysts have raised Avadel Pharmaceuticals' fair value target from $19.00 to $20.20, citing improved commercial execution for Lumryz and pipeline expansion opportunities, though some caution over competition and valuation is noted. Analyst Commentary Bullish analysts highlight commercial execution gains, with improved persistency trends and increasing reimbursed Lumryz patient counts driving revenue upside.Rising Awareness Of Sleep Disorders Will Drive Future Demand
The upward revision in Avadel Pharmaceuticals' consensus price target reflects improved revenue growth expectations and a modest increase in future P/E, resulting in a new fair value estimate of $19.12. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and projected Q3 2025 net product revenue of $71–$75 million.Results: Avadel Pharmaceuticals plc Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 10
Rising Awareness Of Sleep Disorders Will Drive Future Demand
Despite a notable reduction in consensus revenue growth forecasts, the analyst price target for Avadel Pharmaceuticals has increased slightly to $18.00. What's in the News Avadel Pharmaceuticals raised full-year 2025 revenue guidance to $265–$275 million and expects Q3 net product revenue of $71–$75 million.A Piece Of The Puzzle Missing From Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 26% Share Price Climb
Aug 02Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jun 10
LUMRYZ And REVITALYZ Trials Will Unlock Future Value
LUMRYZ's strong market penetration and $1 billion opportunity hint at future revenue growth, with competitive advantage over peers.Market Participants Recognise Avadel Pharmaceuticals plc's (NASDAQ:AVDL) Revenues Pushing Shares 28% Higher
May 04Avadel Pharmaceuticals: Moving To A Speculative Buy
Feb 11The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 26%
Feb 07Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jan 13The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%
Dec 01Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky
Nov 22Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable
Oct 16Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Sep 10Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Stabiliteit en groei van betalingen
Dividenden ophalen
Stabiel dividend: Er zijn onvoldoende gegevens om te bepalen of het dividend per aandeel van AVDL in het verleden stabiel is geweest.
Groeiend dividend: Er zijn onvoldoende gegevens om te bepalen of de dividendbetalingen van AVDL zijn gestegen.
Dividendrendement versus markt
| Avadel Pharmaceuticals Dividendrendement versus markt |
|---|
| Segment | Dividendrendement |
|---|---|
| Bedrijf (AVDL) | n/a |
| Markt onderkant 25% (US) | 1.4% |
| Markt Top 25% (US) | 4.2% |
| Gemiddelde industrie (Pharmaceuticals) | 2.2% |
| Analist prognose (AVDL) (tot 3 jaar) | 0% |
Opmerkelijk dividend: Het dividendrendement van AVDL kan niet worden vergeleken met dat van de onderste 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Hoog dividend: Het dividendrendement van AVDL kan niet worden vergeleken met dat van de top 25% van de dividendbetalers, aangezien het bedrijf geen recente uitbetalingen heeft gerapporteerd.
Winstuitkering aan aandeelhouders
Verdiendekking: Er zijn onvoldoende gegevens om de payout ratio AVDL te berekenen en vast te stellen of de dividendbetalingen worden gedekt door de winst.
Contante uitbetaling aan aandeelhouders
Kasstroomdekking: De duurzaamheid van het dividend kan niet worden berekend, omdat AVDL geen uitbetalingen heeft gerapporteerd.
Ontdek bedrijven met een sterk dividend
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/02/14 10:26 |
| Aandelenkoers aan het einde van de dag | 2026/02/11 00:00 |
| Inkomsten | 2025/09/30 |
| Jaarlijkse inkomsten | 2024/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Avadel Pharmaceuticals plc wordt gevolgd door 8 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| James Molloy | Brean Capital Historical (Janney Montgomery) |
| Jason Butler | Citizens JMP Securities, LLC |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |